Is kevzara safe?

How safe is Kevzara compared to other IL-6 inhibitors?

Kevzara is an interleukin-6 receptor blocker approved for moderate-to-severe rheumatoid arthritis and polymyalgia rheumatica. Clinical studies show its overall safety profile is similar to other drugs in its class, with the most common side effects being injection-site reactions, upper respiratory infections, and elevated liver enzymes. Serious risks include serious infections, gastrointestinal perforations, and changes in blood counts.

Can patients with infections use Kevzara?

Kevzara should not be started in anyone with an active infection. Doctors screen for latent tuberculosis and hepatitis before treatment begins. During therapy, patients who develop signs of infection must stop the drug until the infection clears.

What side effects do patients report most often?

In post-marketing surveillance, the most frequent patient-reported issues are sinus infections, sore throat, and mild injection-site redness. Less common but serious reports include low white blood cell counts and elevated cholesterol levels, both of which require routine blood monitoring.

When does Kevzara's patent expire?

The composition-of-matter patent for sarilumab (Kevzara) expires in the United States in 2027, with potential pediatric exclusivity extending protection until 2028. After expiry, biosimilar versions could enter the market if regulatory and legal hurdles are cleared.

How does Kevzara compare with Actemra?

Both drugs block the IL-6 pathway, but Kevzara is given every two weeks while Actemra can be dosed weekly or every two weeks. Head-to-head data are limited; indirect comparisons suggest similar rates of serious infections, though some rheumatologists note slightly lower injection frequency as a practical advantage for Kevzara.

Are biosimilars expected before patent expiry?

Several companies have filed abbreviated biologic license applications for sarilumab biosimilars. None have launched yet, partly because of ongoing patent litigation. Regulatory reviews in Europe and the United States are expected to conclude around the same time as U.S. patent expiry.

What laboratory monitoring is required?

Patients need complete blood counts, liver-function tests, and lipid panels before starting Kevzara and periodically during treatment. Neutrophil counts below 500 cells/mm³ or liver enzymes more than three times the upper limit of normal usually lead to dose interruption or discontinuation.

Who should avoid Kevzara?

Kevzara is contraindicated in patients with known hypersensitivity to sarilumab. It is not recommended for people with active diverticulitis or recent bowel perforation because of the increased risk of gastrointestinal complications.